Findings of that study showed that ISIKOK-19 CAR-T cells manufactured from 10 relapsed/refractory ALL/NHL patients’ blood managed to eliminate CD19-positive RAJI and DAUDI B cell target models efficiently and specifically, with the exception of the CD19-negative K562 cell line. Here, CD19 is linked to non-Hodgkin lymphoma.